Oral PH - Pulmonary Arterial Hypertension

365 - Switching from PDE5i to Riociguat in the RESPITE Study: Effect on Right Heart Function

Presentation Number
365
Presenter
Co-Authors

Previous Eposter
43 - Molecular Diagnosis of Rejection Phenotypes in 889 Heart Transplant Biopsies: The INTERHEART Study

Next Eposters
453 - Leptin Modifies the Impact of BMI on Heart Failure Progression: The Obesity Paradox Unraveling
502 - Ralinepag, an Oral, Selective, Prostacyclin (IP) Receptor Agonist Consistently Improved Mortality Risk Scores Derived From PAH Registries Across Three Regions: Phase 2 Study Analysis
358 - Ex-vivo Lung Perfusion - 10 Year Follow-up of the First Performed Double LTX With Marginal Donor Lungs Evaluated Using EVLP
367 - OPUS Registry: Switching to Macitentan From Other Endothelin Receptor Antagonists (ERAs)
322 - Bloodstream Infections in Left Ventricular Assist Device Recipients Awaiting Transplantation
178 - By Molecular Analysis, Many ISHLT Histologic Rejection Diagnoses Are Associated With Molecular Injury, Not Molecular Rejection
446 - Sarcopenia of the Psoas Muscles Predicts Survival Following Lung Transplantation
500 - Stroke Volume Response to Exercise is Dependent on Disease Severity in Pulmonary Arterial Hypertension
297 - Is Cold Storage Possible in DCD Heart Transplantation? A Pre-Clinical Study
41 - Pulmonary Endarterectomy: Relationship Between Total Reopened Branches and Outcomes